
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals is viewed favorably because it continues to deliver a strong commercial beat, with 3Q26 Livmarli sales of $133.4M and total net product sales of $186M, while management raised FY26 product guidance to $715M–$720M and expects $10–$15M sequential quarterly revenue growth through 2027. Its outlook is further supported by a diversified late-stage pipeline, including positive Phase 3 EXPAND data for broader cholestatic diseases, the October launch of Atebrioz in FOP, and brelovitug’s positive AZURE-1 results with 4Q26 data and a 1H27 BLA path ahead. The company also remains well capitalized with about $500M in cash and is expected to become cash flow positive next year, reducing financing risk while multiple catalysts approach.
Bears say
Mirum Pharmaceuticals is facing a more fragile fundamental setup because its oral-solution LOE has been moved to 2035, while formulation and method-of-treatment patents may expire in 2031–2032 and the 2040 dosing patents could still be vulnerable to obviousness challenges. The company also carries meaningful execution risk across several unproven indications, since BA, PSC, and PBC all require additional clinical studies and regulatory pathways that are novel or uncharted, with no drugs approved for BA or PSC today. At the same time, greater-than-expected operating expenses and cash burn could force more frequent or less favorable equity raises, while Bylvay and other iBAT inhibitor programs intensify competitive pressure on Livmarli and the broader pipeline.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares